Previous Close | 4.0000 |
Open | 3.9900 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 3.9500 - 4.1000 |
52 Week Range | 1.0400 - 4.9500 |
Volume | |
Avg. Volume | 79,114 |
Market Cap | 45.85M |
Beta (5Y Monthly) | 1.90 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.5700 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for TARA
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS expected in 2H 2024Cash, cash equivalents, and investments of $66M as of December 31, 2023 expected to fund operations into Q2 2025 through several key data milestones NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 9:50 am ET in Boston. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https:
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...